Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More
Xconomy
APRIL 17, 2020
The public markets are moving erratically, but Alnylam Pharmaceuticals showed this week that selling equity isn’t the only way for biotech companies to raise cash. Late last year Alnylam (NASDAQ: ALNY ) began exploring potential royalty deals for inclisiran, a drug that uses RNA interference to lower cholesterol.
84 
Let's personalize your content